Hill August 7, 2024
The popularity of drugs like Ozempic and Mounjaro could grow exponentially in the next few years, both for weight loss and a growing list of potential uses that are being studied.
GLP-1 agonists, a class of medication typically used to treat Type 2 diabetes and obesity, have been available since 2005, but only in the past few years have they transformed weight loss treatment, as well as making billions for the companies that produce the drugs. Health policy research group KFF polling from earlier this year found that 1 in 8 adults have previously taken a GLP-1 agonist and 6 percent of adults are currently on a regimen.
Medicines like semaglutide, tirzepatide and dulaglutide, commercially marketed as Ozempic, Mounjaro...
Today's Sponsors
Today's Sponsor